Different systems. Useful questions. | A question to investigate
US health-system pharmacy | Make the next operational choice defensible
A hospital pharmacy decision rarely belongs to pharmacy alone. A change can affect clinical teams, procurement, finance, discharge and the next organisation receiving the patient. We want to help a US health-system sponsor examine one of those decisions with enough depth to see who carries the work, who receives the benefit and which assumptions would make the proposal fail.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
The first buyer needs a decision mandate
A chief pharmacy officer, service-line leader or finance sponsor may be considering a workflow redesign, an outpatient service or a different use of constrained capacity. The initial brief should name the decision owner and the clinical authority separately. The business incentive is a better case for action and a clearer implementation plan. A finance sponsor’s interest does not confer permission to change treatment or access clinical records.
Supply information is not local capacity
FDA shortage information can provide national context, while the hospital’s inventory and supplier records describe its own situation (FDA, n.d.). We would keep those views separate. A listed shortage does not establish what is available in a particular storeroom; a local stock problem does not prove a national shortage. The evaluation should expose that distinction so a dramatic public signal cannot substitute for the operational evidence needed to decide.
Define the actual unit of work
Rather than begin with an entire medicines budget, we propose selecting one recurring process with a clear beginning and end. It might be the preparation of an outpatient option appraisal or the investigation of supply exceptions. The sponsor would define eligible cases, handovers, responsible roles and completion. We would record where work waits, where it is repeated and what information the next person needs before they can act.
Use a credible retrospective comparison
An initial study could freeze a set of historical cases and compare the current review method with a PHARMORIS-supported review. Inputs could include approved procedure documents, aggregate workflow timestamps and appropriately authorised purchasing information. Reviewers would assess completeness, traceability, preparation effort and disagreement. The exercise would test decision preparation; it would not infer a clinical outcome merely because a report was produced faster.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A US-facing medicines business, analyst or research team deciding whether a public spending comparison is meaningful.
The same medicine. A different denominator.
A spending figure becomes useful when the reader knows the programme, period, unit and exclusions behind it. Reconciliation comes before an attractive price comparison.
A proposition to investigate
A comparable question before a bigger chart.
A public-data brief could identify whether two measures describe sufficiently similar activity to compare. The proposed value is a traceable inclusion decision and a clear definition of the measure. No current price, negotiated saving, purchasing recommendation or live dataset calculation is produced in this specimen.
The reconciliation task is constructed. No records have been joined or analysed in this example.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a defined public-data comparison is valid enough to commission.
- The comparator
- A second explicitly defined source with comparable scope, units and period.
- The evidence
- Source editions, medicine mapping, population, units, exclusions and reproducible inclusion rules.
- Stop or redesign
- Exclude comparisons when the denominator or cost meaning cannot be reconciled; retain the exclusion reason.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefKeep privacy design proportionate
HHS describes formal approaches to de-identification under HIPAA (HHS, n.d.). Removing names from a spreadsheet is not our definition of an adequate privacy process. The local organisation would determine the appropriate authority and safeguards before data use. Wherever the question can be answered with non-identifiable aggregate records, that is the preferable starting point. Any later need for more detailed records would have to justify the additional complexity and risk.
Make displaced work visible
A proposal that saves pharmacy time but adds an equal burden to nursing or finance needs an honest account. We would measure effort across the relevant handovers, distinguish one-time implementation work from recurring delivery and document who reviews an output. A useful evaluation could show that a seemingly attractive option is impractical. That finding has value when it prevents an expensive programme from being presented as an easy saving.
Evidence before a wider agreement
Stop criteria would include unreliable timestamps, an unrepresentative sample, unresolved source errors or a dependency the sponsor cannot control. A wider evaluation would require an agreed benefit measure and a feasible route into existing governance. The commercial discussion would concern the specific decision workflow and its support cost. We would not use a local proof exercise to claim hospital deployment, clinical validation or health-system-wide savings.
Sources and reading context
Official source context checked on 13 October 2026. The study design above is a NEUVIOR proposal for discussion, not a reported deployment or result.
HHS | De-identification guidance
FDA (n.d.) Drug Shortages. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages (Accessed: 14 October 2026).
HHS (n.d.) De-identification guidance. Available at: https://www.hhs.gov/hipaa/for-professionals/special-topics/de-identification/index.html (Accessed: 14 October 2026).
Discuss a health-system decision study
Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.
Another useful angle.
- US health plans | Make the medicines case explicit
Explore a proposed PHARMORIS evidence-preparation study for US health plans, separating benefit design, operational effort and accountable decision-making.
- US specialty pharmacy | Understand the journey before calling it access
A proposed PHARMORIS evaluation of specialty pharmacy referral and administrative handovers, with explicit measures, comparators and data limits.
- US accountable care | Connect a medicines question to the right incentive
A proposed PHARMORIS evaluation for accountable care organisations, focused on a specific medicines-related workflow and appropriately bounded evidence.